The ICC also defines AML with mutated TP53 (≥ 20% PB or BM blasts) as a distinctly aggressive AML, whether presenting de novo, as progression of MDS or as therapy-related disease, because of the dismal prognosis regardless of morphological variant.3,19 Any somatic TP53 mutation with VAF > 10% is sufficient for this diagnosis. This evidence concerns the gene TP53 and myelodysplastic syndrome.